Literature DB >> 26038231

Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.

Anders Aune Tveita1, Fredrik Schjesvold2, Ole Audun Haabeth2, Marte Fauskanger2, Bjarne Bogen3.   

Abstract

Tumors cells can escape cytotoxic CD8+ T cells by preventing MHC I display of tumor antigens. It is unknown how tumors evade CD4+ T-cell responses, but because many tumor cells lack MHC II expression, novel mechanisms would be required. We have investigated this issue in a model in which MHC II(NEG) myeloma cells secrete a monoclonal Ig containing a V region L chain (VL) epitope recognized by CD4+ T cells. Infiltrating macrophages process and present the secreted tumor antigen to Th1 cells, resulting in induction of macrophage cytotoxicity and apparent rejection of the tumor. Despite long-term tumor protection in VL-specific T-cell receptor transgenic mice, we here describe that some myeloma cells persisted in a dormant state and, eventually, formed expanding tumors. Escape tumor cells maintained their secretion of complete (H+L) monoclonal Ig with unchanged sequence, while secretion of surplus free L chain was severely diminished. Although free L chains were efficiently processed and presented by tumor-infiltrating macrophages to CD4+ T cells, complete (H+L) monoclonal Ig was not. Forced overexpression of free L chain secretion reinstated tumor rejection. These results show that tumors can escape CD4+ T-cell-mediated rejection by impairing indirect presentation of tumor antigen by infiltrating macrophages. This occurs through a novel mechanism of immunoediting, in which modulation of the quaternary structure of the secreted tumor-specific antigen reduces its immunogenicity. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26038231     DOI: 10.1158/0008-5472.CAN-14-3640

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.

Authors:  W He; C Wang; R Mu; P Liang; Z Huang; J Zhang; L Dong
Journal:  Oncogene       Date:  2017-03-27       Impact factor: 9.867

Review 2.  Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

Authors:  Fotis Asimakopoulos; Chelsea Hope; Michael G Johnson; Adam Pagenkopf; Kimberly Gromek; Bradley Nagel
Journal:  J Leukoc Biol       Date:  2017-03-02       Impact factor: 4.962

3.  Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice.

Authors:  D Wang; Y Fløisand; C V Myklebust; S Bürgler; A Parente-Ribes; P O Hofgaard; B Bogen; K Taskén; G E Tjønnfjord; F Schjesvold; J Dalgaard; A Tveita; L A Munthe
Journal:  Leukemia       Date:  2017-02-24       Impact factor: 11.528

4.  Neoantigen Presentation and IFNγ Signaling on the Same Tumor-associated Macrophage are Necessary for CD4 T Cell-mediated Antitumor Activity in Mice.

Authors:  Ainhoa Perez-Diez; Xiangdong Liu; Polly Matzinger
Journal:  Cancer Res Commun       Date:  2022-05-09

5.  Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.

Authors:  Stephen Iwanowycz; Junfeng Wang; Johnie Hodge; Yuzhen Wang; Fang Yu; Daping Fan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

6.  Polarity of CD4+ T cells towards the antigen presenting cell is regulated by the Lck adapter TSAd.

Authors:  Greger Abrahamsen; Vibeke Sundvold-Gjerstad; Meseret Habtamu; Bjarne Bogen; Anne Spurkland
Journal:  Sci Rep       Date:  2018-09-06       Impact factor: 4.379

7.  Have Cells Harboring the HIV Reservoir Been Immunoedited?

Authors:  Szu-Han Huang; Chase D McCann; Talia M Mota; Chao Wang; Steven M Lipkin; R Brad Jones
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

8.  CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.

Authors:  Ole Audun W Haabeth; Kjartan Hennig; Marte Fauskanger; Geir Åge Løset; Bjarne Bogen; Anders Tveita
Journal:  Blood Adv       Date:  2020-06-23

9.  Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?

Authors:  Laetitia Sordé; Sebastian Spindeldreher; Ed Palmer; Anette Karle
Journal:  Immun Inflamm Dis       Date:  2017-05-31

10.  Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.

Authors:  Anders Tveita; Marte Fauskanger; Bjarne Bogen; Ole Audun Werner Haabeth
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.